当前位置: X-MOL 学术Mol. Cancer Ther. › 论文详情
Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer.
Molecular Cancer Therapeutics ( IF 4.856 ) Pub Date : 2020-03-01 , DOI: 10.1158/1535-7163.mct-19-0940
Waleed S Al Amri,Lisa M Allinson,Diana E Baxter,Sandra M Bell,Andrew M Hanby,Stacey J Jones,Abeer M Shaaban,Lucy F Stead,Eldo T Verghese,Thomas A Hughes

Poor-prognosis breast cancers are treated with cytotoxic chemotherapy, but often without any guidance from therapy predictive markers because universally accepted markers are not currently available. Treatment failure, in the form of recurrences, is relatively common. We aimed to identify chemotherapy predictive markers and resistance pathways in breast cancer. Our hypothesis was that tumor cells remaining after neoadjuvant chemotherapy (NAC) contain somatic variants causing therapy resistance, while variants present pre-NAC but lost post-NAC cause sensitivity. Whole-exome sequencing was performed on matched pre- and post-NAC cancer cells, which were isolated by laser microdissection, from 6 cancer cases, and somatic variants selected for or against by NAC were identified. Somatic variant diversity was significantly reduced after therapy (P < 0.05). MUC17 variants were identified in 3 tumors and were selected against by NAC in each case, while PCNX1 variants were identified in 2 tumors and were selected for in both cases, implicating the function of these genes in defining chemoresponse. In vitro knockdown of MUC17 or PCNX1 was associated with significantly increased or decreased chemotherapy sensitivity, respectively (P < 0.05), further supporting their roles in chemotherapy response. Expression was tested for predictive value in two independent cohorts of chemotherapy-treated breast cancers (n = 53, n = 303). Kaplan-Meier analyses revealed that low MUC17 expression was significantly associated with longer survival after chemotherapy, whereas low PCNX1 was significantly associated with reduced survival. We concluded that therapy-driven selection of somatic variants allows identification of chemotherapy response genes. With respect to MUC17 and PCNX1, therapy-driven selection acting on somatic variants, in vitro knockdown data concerning drug sensitivity, and survival analysis of expression levels in patient cohorts all define the genes as mediators of and predictive markers for chemotherapy response in breast cancer.
更新日期:2020-04-01

 

全部期刊列表>>
聚焦商业经济政治法律
跟Nature、Science文章学绘图
智控未来
控制与机器人
化学研究精选
欢迎探索2019年最具下载量的地球科学论文
招募海内外科研人才,上自然官网
基因组学对精准公共卫生的影响,专辑征稿
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
x-mol收录
湖南大学化学化工学院刘松
上海有机所
李旸
大连化物所
香港大学
X-MOL
支志明
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug